MET and lung cancer: To develop a mouse model that could recapitulate osimertinib resistance caused by MET amplification in patients with EGFR-mutated lung cancer, we took advantage of a mouse strain in which liver carcinoma develops upon induction of human WT MET expression in the liver [7].